about
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsMembrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.Predictive biomarkers for dasatinib treatment in melanoma.Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanomaPreclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesIn vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerProspects for non-immunological molecular therapeutics in melanoma.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.2D-DIGE analysis of phospho-enriched fractions from dasatinib-treated melanoma cell lines.Metabolomic studies of human lung carcinoma cell lines using in vitro (1)H NMR of whole cells and cellular extracts.Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAILGermline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancerFrequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancerCombined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancerPilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 triaDasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
P50
Q21093314-FAFF9AFD-92A6-434E-81B8-0BD2F5A2445EQ33783032-57FB31B9-8022-4882-B6E2-76C1497B99B8Q34781153-A1F0C7B6-61F3-4743-AA14-B2D2639D3B42Q35706499-5F5CF43C-D2DD-4AFB-9825-138589497564Q36940730-4AF37E02-788E-4823-B284-0DD5F8ED0D93Q37621597-A8F45B3C-4C0D-40F3-B324-2EA56C441610Q37688976-AA4C462A-B1FA-4F29-8B6F-68E63A0D9732Q37736373-74435C88-0E7D-439F-A92C-5B8E74E47435Q38301236-48924C10-A3E4-4398-A393-205D46AA981EQ39250672-3C41D7DF-854B-4411-9548-FFD49789F3AEQ39607566-212F36BA-0719-4D8F-BD34-7E9D43C6BB2BQ39983567-6D1A26C9-09EF-442D-87E4-E2B914861B7BQ41149668-508256C8-6A71-4F06-BA8E-0F345E5B6B54Q42396417-33AB889A-7725-421F-ABCF-34C6C6931656Q46780069-63E5BF0C-46F9-4833-8C4A-C108940DE654Q48138303-E87996CF-ECF2-4045-8754-C172F88C0707Q49357108-BB14B763-EDA8-427E-BEAE-1E750BE7609EQ51023478-81218D0D-5AFE-48CE-A31E-80B1EB740C0DQ57279753-358C90AC-95D8-491B-B96D-DF7DEF420C61Q58803839-01D67ACB-D689-47DD-AC50-5E6AC862777BQ61987563-34AF6B75-5989-4F31-87C2-E44C195D438EQ62720031-8506CDF1-D14D-4695-8C8A-FAD5C7914EBAQ89736721-D6ABDFD1-C8D0-4AF8-A3A0-BC7324F3C872Q92434457-A2C5A614-58E2-453D-A18B-1F3314DD587FQ93182168-5E751C8B-274D-4672-B0FA-C6CA53FD8B64
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alex J. Eustace
@ast
Alex J. Eustace
@en
Alex J. Eustace
@es
Alex J. Eustace
@nl
type
label
Alex J. Eustace
@ast
Alex J. Eustace
@en
Alex J. Eustace
@es
Alex J. Eustace
@nl
altLabel
Alex
@en
prefLabel
Alex J. Eustace
@ast
Alex J. Eustace
@en
Alex J. Eustace
@es
Alex J. Eustace
@nl
P106
P1153
23666661200
P21
P31
P496
0000-0002-4092-1360